Vortioxetine (Brintellix®)

Assessment Status Assessment process complete
Drug Vortioxetine
Brand Brintellix®
Indication For the treatment of major depressive episodes in adults.
Assessment Process
Rapid review commissioned 01/10/2014
Rapid review completed 14/11/2014
Rapid review outcome Full Pharmacoeconomic Evaluation Recommended
NCPE assessment outcome Reimbursement Not Recommended

Technical Summary

The HSE has approved reimbursement following confidential price negotiations October 2017.